Pseudoprogression in Lung Cancer after Immunotherapy Treatment
Naiyer A. Rizvi, MD, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.
Clinical Pearls:
- Early scans that appear to be tumor growth may actually be delayed benefit of the treatment or inflammation of the tumor as T cells become active
- This phenomenon occurs in less than 10% of patients
- Physicians should consider the patient’s well being in addition to scans in order to make a decision
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
